Full Press Release Details
Green Med Solution, Inc.
GREEN MED SOLUTION Reports FOURTH quarter AND FULL YEAR 2025 financial results and provides business update
LUMPUR, MALAYSIA, March 30, 2026 - Bio Green Med Solution, Inc. ("BGMS," the "Company" or "we,"
formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection
and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.
was a productive year for BGMS, marked by the acquisition of Fitters Sdn. Bhd., a fire safety materials and equipment company, on September
12, 2025, the liquidation of our U.K. subsidiary and the sale of our Plogosertib drug, transactions which strengthened our balance sheet.
We used this momentum to chart our new focus towards continued growth in the company," said Datuk Dr. Doris Wong Sing EE, Chief
Executive Officer of BGMS.
Quarter 2025 Key Accomplishments and Recent Highlights
| In October, the Company entered into an Asset Purchase Agreement with Tethra Biosciences Inc., a Delaware corporation, in which the Company agreed to sell certain assets, including all of the Company's patent rights related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies for a purchase price of $300,000, plus a further potential Milestone payment of $170,000. | ||
| In November, the Company entered into a Warrant Exchange Agreement with holders of certain existing warrants of the Company, which were exchanged for 1,402,605 shares of the Company's common stock, par value $0.001 per share, which warrants were originally issued pursuant to a securities purchase agreement dated as of June 20, 2025. | ||
| In January 2026, the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which was paid on February 1, 2026, to holders of record as of the close of business on January 22, 2026. |
of December 31, 2025, cash and cash equivalents totaled $3.5 million, compared to $3.8 million as of December 31, 2024.
cash used in operating activities was $4.8 million for the twelve months ended December 31, 2025 compared to $8.0 million for the same
period of 2024. The Company estimates that its current cash resources will fund planned expenditure into the third quarter of 2026.
the acquisition of Fitters Sdn. Bhd. on September 12, 2025, product revenue from sales and distribution of fire safety equipment was
$0.7 million for both the three months and year ended December 31, 2025.
of sales related to sales and distribution of fire safety equipment were $0.5 million and $0.6 million for the three months and year
ended December 31, 2025.
and development (R&D) expenses were $0 and $0.8 million for the three months and year ended December 31, 2025, as compared to $0.9
million and $6.7 million for the same period in 2024. R&D expenses relating to the Company's previously-owned drug candidate,
fadraciclib, were $0 and $0.4 million for the three months and year ended December 31, 2025, as compared to $0.8 million and $5.0 million
for the same period in 2024. Expenditure for the Fadraciblib program ceased as a result of the Company's UK subsidiary, Cyclacel
Limited, being liquidated on January 24, 2025. R&D expenses related to plogosertib were $0 and $0.4 million for the three months
and year ended December 31, 2025, as compared to $0.1 million and $1.6 million for the same period in 2024. Research and development
expenses relating to plogosertib were paused as we explored an alternative salt, oral formulation with improved bioavailability. Plogosertib
was subsequently sold in October 2025.
and administrative expenses for the three months and year ended December 31, 2025, were $1.3 million and $7.7 million, compared to $0.9
million and $5.4 million for the same period of the previous year due primarily to several one-time costs associated with the two changes
of control of the Company during 2025.
other income, net, for the three months and year ended December 31, 2025, was $0.5 million and $5.4 million, compared to an expense of
$30,000 and income of $10,000 for the same period of the previous year. The increase of $5.4 million for the year ended December 31,
2025, is primarily related to a $4.9 million gain on deconsolidation of our former subsidiary Cyclacel Limited and a $0.3 million receipt
from the sale of our research and development anti-mitotic asset, plogosertib in early October 2025.
tax charges for the three months and year ended December 31, 2025 were $5,000 and $7,000 compared to a charge of $1.2 million and benefit
of $0.8 million for the same period of the previous year. Both the tax charge and benefit during the prior periods related to UK research
and development tax credits associated with our former subsidiary Cyclacel Limited. There were no research and development tax credits
for the three months and year ended December 31, 2025, following the liquidation of the UK subsidiary and the subsequent loss of eligibility
for recoverable tax credits as a result thereof.
loss for the three months and year ended December 31, 2025, was $0.6 million and $3.0 million (including stock based compensation expense
of $0.7 million and $2.3 million respectively), compared to $3.0 million and $11.2 million (including stock based compensation expense
of $0.1 million and $0.6 million respectively) for the same period in 2024.
Bio Green Med Solution, Inc.
is a diversified company that was formerly engaged in
the biopharmaceutical industry but as of September 2025 has shifted its operations to focus on provision of fire safety protection and
distribution activities. Specifically, on September 12, 2025, the Company completed its acquisition of Fitters Sdn. Bhd., a Malaysia-based
group specializing in fire protection products and services. Headquartered in Malaysia, the Company is now focused on advancing opportunities
across these distinct sectors whilst maintaining its commitment to driving long-term value creation for shareholders. For
additional information, please visit www.bgmsglobal.com.
for historical information, certain matters discussed in this press release may be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance
and involve various assumptions, known and unknown risks, uncertainties and other factors that may cause our actual results, levels of
activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by words such as
"may," "will," "should," "expects," "intends," "plans," "anticipates,"
"believes," "estimates," "predicts," "potential" or other comparable words. Actual results,
performance or outcomes may differ materially from those expressed or implied by these forward-looking statements and may not align with
historical performance and events due to a number of factors, including those discussed in the sections of our annual report on Form
10-K entitled "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors," and those discussed
in our Form 10-Q quarterly reports filed after such annual report. BGMS's SEC filings are readily obtainable at no charge at www.sec.gov,
as well as on its own investor relations website at https://investor.bgmsglobal.com/sec-filings. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements,
and caution should be exercised against placing undue reliance upon such statements, which are based only on information currently available
to us and speak only as of the date hereof. We are under no duty to update publicly any of the forward-looking statements after the date
of this earnings press release, whether as a result of new information, future events or otherwise, except as required by law.
Green Med Solution, Inc.
GREEN MED SOLUTION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
$000s, except share and per share amounts)
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue - fire safety | $ | 666 | $ | - | $ | 747 | $ | - | ||||||||
| Clinical trial supply | - | - | - | 43 | ||||||||||||
| Revenues | $ | 666 | $ | - | 747 | 43 | ||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales | 545 | - | 609 | - | ||||||||||||
| Research and development | (47 | ) | 880 | 848 | 6,655 | |||||||||||
| General and administrative | 1,250 | 946 | 7,717 | 5,392 | ||||||||||||
| Total operating expenses | 1,748 | 1,826 | 9,174 | 12,047 | ||||||||||||
| Operating loss | (1,082 | ) | (1,826 | ) | (8,427 | ) | (12,004 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Foreign exchange gains (losses) | 98 | (60 | ) | 73 | (54 | ) | ||||||||||
| Interest income | 45 | 30 | 62 | 12 | ||||||||||||
| Gain on deconsolidation of subsidiary | - | - | 4,947 | - | ||||||||||||
| Other income, net | 333 | - | 354 | 52 | ||||||||||||
| Total other income, net | 476 | (30 | ) | 5,436 | 10 | |||||||||||
| Loss before taxes | (606 | ) | (1,856 | ) | (2,991 | ) | (11,994 | ) | ||||||||
| Income tax benefit (charge) | (5 | ) | (1,194 | ) | (7 | ) | 782 | |||||||||
| Net loss | (611 | ) | (3,050 | ) | (2,998 | ) | (11,212 | ) | ||||||||
| Dividend on convertible exchangeable preferred shares | (20 | ) | - | (61 | ) | - | ||||||||||
| Deemed dividend on warrant exchange | (9,539 | ) | - | (11,033 | ) | - | ||||||||||
| Net loss applicable to common shareholders | $ | (10,170 | ) | $ | (3,050 | ) | $ | (14,092 | ) | $ | (11,212 | ) | ||||
| Basic and diluted earnings per common share: | ||||||||||||||||
| Net loss per share - basic and diluted (common shareholders) | $ | (2.21 | ) | $ | (847.61 | ) | $ | (6.45 | ) | $ | (502.46 | ) | ||||
| Weighted average common shares outstanding | 4,606,822 | 3,597 | 2,185,075 | 22,314 |
GREEN MED SOLUTION, INC.
$000s, except share, per share, and liquidation preference amounts)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,505 | $ | 3,137 | ||||
| Accounts receivable | 1,257 | - | ||||||
| Inventory | 1,384 | - | ||||||
| Prepaid expenses and other current assets | 110 | 537 | ||||||
| Total current assets | 6,256 | 3,674 | ||||||
| Property and equipment, net | 137 | 3 | ||||||
| Right-of-use lease asset | 12 | 5 | ||||||
| Goodwill | 1,570 | - | ||||||
| Non-current deposits | 210 | 412 | ||||||
| Total assets | $ | 8,185 | $ | 4,094 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 617 | $ | 4,599 | ||||
| Accrued and other current liabilities | 715 | 1,669 | ||||||
| Other liabilities measured at fair value | - | - | ||||||
| Total current liabilities | 1,332 | 6,268 | ||||||
| Lease liability | 2 | - | ||||||
| Other liabilities | 9 | - | ||||||
| Total liabilities | 1,343 | 6,268 | ||||||
| Stockholders' equity | 6,842 | (2,174 | ) | |||||
| Total liabilities and stockholders' equity | $ | 8,185 | $ | 4,094 |